Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + GP chemotherapy + toripalimab for multiple metastatic nasopharyngeal carcinoma
ChiCTR2500110015Phase 3Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of toripalimab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: One-year progression-free survival (PFS). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2500110015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110015.